Marketed Stage Deals and Alliances of 2013

Date: August 1, 2014
Pages: 200
Price:
US$ 1,495.00 US$ 1,196.00
Offer valid until December 31, 2014!
License [?]:
Publisher: CurrentPartnering
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), CD-ROM Mail Delivery, E-mail Delivery (Word)
ID: MAC2383B9D8EN
Leaflet:

Download PDF Leaflet

Marketed Stage Deals and Alliances of 2013
The Marketed Stage Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013.

Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.

The initial chapters of this report provide an orientation of 2013’s dealmaking and business activities.

Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication.

Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013.

The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2013.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013.
CHAPTER 1 – TRENDS IN DEALMAKING DURING 2013

1.1. Bigpharma dealmaking activity
1.2. Partnering by deal type
1.3. Partnering by industry sector
1.4. Partnering by stage of development
1.5. Partnering by technology type
1.6. Partnering by therapy area

CHAPTER 2 – LEADING DEALS DURING 2013

2.1. Introduction
2.2. Top deals by value during 2013

CHAPTER 3 – BIGPHARMA DEALS DURING 2013

3.1. Introduction
3.2. How to use bigpharma partnering deals
3.3. Bigpharma partnering company profiles for 2013
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene

CSL

Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

CHAPTER 4 – PARTNERING DEALS DIRECTORY 2013

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By stage of development
4.5. By technology type
4.6. By therapy area

ABOUT WILDWOOD VENTURES

Current Partnering
Current Agreements
Current Reports
Recent titles from CurrentPartnering
Order Form – Reports

TABLE OF FIGURES

Figure 1: Bigpharma – top 50 – January to December 2013
Figure 2: Bigpharma deal frequency – 2013
Figure 3: Partnering by deal type during 2013
Figure 4: Partnering by industry sector during 2013
Figure 5: Partnering by stage of development during 2013
Figure 6: Partnering by technology type during 2013
Figure 7: Partnering by therapy area during 2013
Figure 8: Top deals by value during 2013
Clinical Stage Deals and Alliances of 2013 US$ 1,196.00 Aug, 2014 · 200 pages
Discovery Stage Deals and Alliances of 2013 US$ 1,196.00 Aug, 2014 · 200 pages
Pre-Clinical Stage Deals and Alliances of 2013 US$ 1,196.00 Aug, 2014 · 200 pages
Cell Therapy Deals and Alliances of 2013 US$ 1,196.00 Aug, 2014 · 200 pages
Companion Diagnostics Deals and Alliances of 2013 US$ 1,196.00 Aug, 2014 · 200 pages

Ask Your Question

Marketed Stage Deals and Alliances of 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: